Iron‐Catalyzed trans ‐Hydrostannation of Terminal Alkynes
Angewandte Chemie · 06.10.2025 · 137 (41)
DOI: 10.1002/ange.202514794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie, online erschienen am 21.08.2025. Verfasst von Soumyadeep Chakrabortty und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The readily accessible iron complex [Cp*FeCl(tmeda)] is an effective catalyst for the highly regio‐ and stereoselective trans ‐hydrostannylation of terminal alkyl alkynes, affording a type of alkenylstannanes that is difficult to make otherwise. The R 3 Sn‐ moiety is faithfully delivered to the terminal C‐atom, unless a propargylic or homo‐propargylic ─OH or ─NH 2 group is present in the substrate, which (partly or fully) inverts the regiochemical course; this steering effect, however, can be switched off upon protection of the protic site. The trans ‐addition likely starts by insertion of the [Cp*FeCl] fragment into the R 3 Sn─H bond, followed by a migratory insertion of the ligated alkyne into the Fe─Sn unit of the Fe(IV) species thus formed. This “modified Chalk–Harrod” mechanism is manifested in a stannylative cyclization of 1,6‐enyne derivatives, which has hardly any precedent either; a pathway via iron vinylidene intermediates can be excluded on the basis of deuterium labeling experiments.
Zitieren
APA
Chakrabortty, S., & Fürstner, A. (2025). Iron‐Catalyzed trans ‐Hydrostannation of Terminal Alkynes. Angewandte Chemie, 137(41). https://doi.org/10.1002/ange.202514794
Vancouver
Chakrabortty S, Fürstner A. Iron‐Catalyzed trans ‐Hydrostannation of Terminal Alkynes. Angewandte Chemie. 2025;137(41). doi:10.1002/ange.202514794
BibTeX
@article{Chakrabortty2025,
author = {Chakrabortty, Soumyadeep and Fürstner, Alois},
title = {Iron‐Catalyzed trans ‐Hydrostannation of Terminal Alkynes},
journal = {Angewandte Chemie},
year = {2025},
volume = {137},
number = {41},
doi = {10.1002/ange.202514794}
}
EUVIMED